Abstract | OBJECTIVE: To review and summarize data on olaratumab, which was approved by the US Food and Drug Administration (FDA) in October 2016, in combination with doxorubicin, for the treatment of advanced soft tissue sarcoma. DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: DATA SYNTHESIS: CONCLUSION:
|
Authors | Benjamin J Andrick, Arpita Gandhi |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 51
Issue 12
Pg. 1090-1098
(Dec 2017)
ISSN: 1542-6270 [Electronic] United States |
PMID | 28778132
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Doxorubicin
- Receptor, Platelet-Derived Growth Factor alpha
- olaratumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, economics, pharmacology, therapeutic use)
- Antineoplastic Agents
(adverse effects, economics, pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, economics, pharmacology, therapeutic use)
- Doxorubicin
(adverse effects, economics, therapeutic use)
- Drug Costs
- Humans
- Receptor, Platelet-Derived Growth Factor alpha
(antagonists & inhibitors)
- Sarcoma
(drug therapy, economics, metabolism)
- Treatment Outcome
|